Zack Armen, Head of Investor Relations at Agenus, shared a post on LinkedIn:

”Yesterday we announced a major transaction with Ligand Pharmaceuticals, who committed $100M ($75M upfront) as part of a Royalty Financing agreement including six of our partnered programs + our lead combo asset, BOT/BAL. This transaction strengthens Agenus’ balance sheet and our strategic positioning as we head toward key development and regulatory inflection points in the BOT/BAL program.

We thank our new partners at Ligand for their support and shared conviction in BOT/BAL’s potential to help patients in need across the solid tumor landscape. Details of the transaction can be found here.”

Source: Zack Armen/LinkedIn